Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Which of the following biologic agents is classified as a monoclonal antibody that targets free immunoglobulin E to prevent mast cell sensitization in allergic asthma?
Correct Answer
C — Omalizumab
Rationale
Omalizumab is classified as an anti-IgE monoclonal antibody. It binds free IgE in circulation at the same site recognized by the high-affinity IgE receptor on mast cells and basophils, preventing IgE from attaching to cell surfaces and initiating allergic sensitization. Mepolizumab targets interleukin-5. Benralizumab targets the interleukin-5 receptor alpha subunit. Dupilumab targets the interleukin-4 receptor alpha subunit.
Question 2
Which of the following biologic agents is classified as a monoclonal antibody that directly neutralizes interleukin-5 and is administered subcutaneously every four weeks?
Correct Answer
A — Mepolizumab
Rationale
Mepolizumab is classified as an anti-interleukin-5 monoclonal antibody administered subcutaneously every four weeks. It binds and neutralizes interleukin-5 directly, reducing eosinophil production, recruitment, and survival. Benralizumab targets the interleukin-5 receptor alpha subunit rather than the cytokine itself, and has a distinct dosing schedule. Reslizumab also neutralizes interleukin-5 directly but is administered intravenously. Tezepelumab targets thymic stromal lymphopoietin, an upstream epithelial cytokine.
Question 3
Which of the following biologic agents is classified as an afucosylated monoclonal antibody targeting the interleukin-5 receptor alpha subunit, an engineering modification that enables antibody-dependent cellular cytotoxicity of eosinophils?
Correct Answer
D — Benralizumab
Rationale
Benralizumab is classified as an afucosylated monoclonal antibody that targets the interleukin-5 receptor alpha subunit on eosinophils and basophils. Afucosylation enhances binding to Fc gamma receptor III on natural killer cells and macrophages, triggering antibody-dependent cellular cytotoxicity and near-complete eosinophil depletion. Mepolizumab and reslizumab target interleukin-5 directly and are not afucosylated. Dupilumab targets the interleukin-4 receptor alpha subunit.
Question 4
Which of the following biologic agents is classified as a monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, simultaneously preventing both interleukin-4 and interleukin-13 from signaling?
Correct Answer
B — Dupilumab
Rationale
Dupilumab is classified as a monoclonal antibody targeting the interleukin-4 receptor alpha subunit, the shared component of both the type I interleukin-4 receptor and the type II receptor through which interleukin-13 signals on non-hematopoietic cells. Blocking this shared subunit prevents both interleukin-4 and interleukin-13 signaling simultaneously. Omalizumab targets IgE. Mepolizumab targets interleukin-5. Benralizumab targets the interleukin-5 receptor alpha subunit.
Question 5
Which of the following anti-interleukin-5 agents is classified as requiring intravenous administration and is approved only for adult patients with blood eosinophils at or above 400 cells per microliter?
Correct Answer
C — Reslizumab
Rationale
Reslizumab is classified as an anti-interleukin-5 monoclonal antibody requiring intravenous administration every four weeks, approved for adult patients with blood eosinophil counts at or above 400 cells per microliter — the highest eosinophil threshold among approved anti-interleukin-5 agents. Mepolizumab is subcutaneous with a lower eosinophil threshold and is approved from age six onward. Benralizumab targets the interleukin-5 receptor alpha subunit and is subcutaneous. Tezepelumab targets thymic stromal lymphopoietin rather than interleukin-5.
Question 6
Which of the following biologic agents is classified as targeting thymic stromal lymphopoietin, an upstream epithelial cytokine, and is notable for demonstrating efficacy regardless of baseline blood eosinophil count?
Correct Answer
A — Tezepelumab
Rationale
Tezepelumab is classified as a monoclonal antibody targeting thymic stromal lymphopoietin, an epithelial-derived cytokine that initiates type 2 immune activation by stimulating innate lymphoid cells and dendritic cells upstream of the interleukin-4, interleukin-5, and interleukin-13 cascade. By acting at this upstream initiating step, tezepelumab demonstrates efficacy across severe asthma phenotypes including patients with low blood eosinophil counts, unlike anti-interleukin-5 agents which require eosinophilia for eligibility. Mepolizumab targets interleukin-5. Omalizumab targets IgE. Dupilumab targets the interleukin-4 receptor alpha subunit.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
Omalizumab prevents allergic asthma exacerbations through two sequential effects on mast cell IgE receptor biology. Which of the following correctly describes both mechanisms?
Correct Answer
D — Omalizumab binds free IgE at the high-affinity receptor binding site, preventing mast cell sensitization, and secondarily downregulates high-affinity IgE receptor expression on mast cells and basophils
Rationale
Omalizumab works through two sequential mechanisms. The primary effect is direct: it binds free IgE in circulation at the same epitope recognized by the high-affinity IgE receptor, preventing IgE from loading onto mast cell and basophil surfaces. Without surface-bound IgE, allergen crosslinking cannot occur and degranulation is suppressed. The secondary effect develops over weeks of treatment: reduced free IgE leads to downregulation of high-affinity IgE receptor expression on mast cells and basophils, further reducing cellular sensitivity to any remaining surface IgE. Omalizumab does not displace IgE already bound to mast cell receptors, does not activate complement, and does not directly affect B cell class switching.
Question 8
Omalizumab dosing in severe allergic asthma is individualized rather than weight-based alone. Which of the following correctly describes how omalizumab doses are determined and what patient characteristic limits eligibility?
Correct Answer
B — Dose is determined by both baseline serum total IgE level and body weight using a prescribing table; patients with IgE outside the eligible range are not candidates
Rationale
Omalizumab dosing is uniquely determined by two variables simultaneously: baseline serum total IgE level and body weight, combined using a prescribing table that specifies subcutaneous doses of 150 to 375 mg every two to four weeks. Patients whose IgE levels fall outside the table range — either too low or too high — are not eligible for omalizumab. This IgE-based dosing reflects the drug's mechanism: the dose must be sufficient to neutralize the patient's circulating IgE burden. Blood eosinophil count and fractional exhaled nitric oxide guide anti-interleukin-5 and anti-interleukin-4 receptor alpha agent selection, not omalizumab dosing.
Question 9
Benralizumab depletes eosinophils more completely than mepolizumab or reslizumab despite all three targeting the interleukin-5 pathway. Which of the following best explains the mechanism responsible for benralizumab's superior eosinophil depletion?
Correct Answer
C — Benralizumab's afucosylated Fc region enhances binding to Fc gamma receptor III on natural killer cells and macrophages, triggering antibody-dependent cellular cytotoxicity of eosinophils
Rationale
Benralizumab is engineered without fucose sugar on its Fc region — a modification called afucosylation that dramatically enhances affinity for Fc gamma receptor III on natural killer cells and macrophages. When benralizumab binds the interleukin-5 receptor alpha subunit on eosinophils, the exposed afucosylated Fc region recruits natural killer cells and macrophages that kill the eosinophil through antibody-dependent cellular cytotoxicity. This direct cell-killing mechanism adds to the cytokine blockade effect and accounts for the near-complete eosinophil depletion benralizumab achieves — a more profound reduction than the cytokine neutralization alone achieved by mepolizumab or reslizumab.
Question 10
Mepolizumab and benralizumab both reduce blood and tissue eosinophil counts in severe eosinophilic asthma, but through different molecular targets. Which of the following correctly identifies the mechanistic distinction between these two agents?
Correct Answer
A — Mepolizumab neutralizes interleukin-5 in circulation, preventing it from binding the receptor; benralizumab blocks the interleukin-5 receptor alpha subunit directly and also depletes eosinophils via antibody-dependent cellular cytotoxicity
Rationale
Mepolizumab binds and neutralizes interleukin-5 directly in the circulation, preventing the cytokine from interacting with the interleukin-5 receptor on eosinophil precursors and mature eosinophils. This reduces eosinophil production, recruitment, and survival through cytokine deprivation. Benralizumab targets the interleukin-5 receptor alpha subunit on eosinophils and basophils directly. Beyond blocking interleukin-5 signaling, its afucosylated Fc region recruits natural killer cells to kill receptor-expressing eosinophils through antibody-dependent cellular cytotoxicity — a direct cellular depletion mechanism absent from mepolizumab. This distinction explains benralizumab's more profound eosinophil depletion.
Question 11
Dupilumab blocks the interleukin-4 receptor alpha subunit and simultaneously interrupts both interleukin-4 and interleukin-13 signaling. Which of the following correctly explains the structural basis for this dual cytokine blockade with a single antibody?
Correct Answer
D — Interleukin-4 receptor alpha is the shared component of both the type I receptor for interleukin-4 and the type II receptor for both interleukin-4 and interleukin-13; blocking it interrupts both cytokines' signaling simultaneously
Rationale
The interleukin-4 receptor alpha subunit is the shared structural component of two distinct receptor complexes. The type I receptor, found on hematopoietic cells, consists of interleukin-4 receptor alpha paired with the common gamma chain and mediates interleukin-4 signaling. The type II receptor, found on non-hematopoietic cells including airway epithelium and smooth muscle, consists of interleukin-4 receptor alpha paired with the interleukin-13 receptor alpha-1 subunit and mediates both interleukin-4 and interleukin-13 signaling on these cells. Because interleukin-4 receptor alpha is required for both complexes to function, a single antibody blocking this subunit simultaneously prevents both interleukin-4 and interleukin-13 from signaling through their respective receptor complexes — not because dupilumab is bispecific, but because both cytokines share a required structural component.
Question 12
Among the anti-interleukin-5 biologic agents, blood eosinophil count is the primary eligibility biomarker. Which of the following correctly describes the eosinophil threshold most consistently associated with clinical response to anti-interleukin-5 therapy?
Correct Answer
B — 300 cells per microliter or above is the threshold most consistently associated with clinical response; 150 cells per microliter serves as lower-boundary eligibility for some agents
Rationale
Blood eosinophil count at or above 300 cells per microliter is the threshold most consistently associated with clinical response to anti-interleukin-5 agents, producing meaningful reductions in exacerbation frequency and oral corticosteroid burden. Counts at or above 150 cells per microliter serve as lower-boundary eligibility criteria for some agents — particularly mepolizumab — reflecting that some clinical benefit may occur at intermediate eosinophil levels, though the magnitude is greater at higher counts. The 300 cells per microliter threshold reflects the level at which eosinophilic airway inflammation is reliably driven by interleukin-5, making interleukin-5 pathway blockade therapeutically meaningful.
Question 13
Fractional exhaled nitric oxide is used as a biomarker to guide biologic selection in severe asthma. Which of the following best explains what elevated fractional exhaled nitric oxide reflects at the cellular and molecular level?
Correct Answer
C — Elevated fractional exhaled nitric oxide reflects interleukin-13 and interleukin-4-driven eosinophilic airway inflammation, and values above 25 parts per billion suggest type 2 high disease
Rationale
Fractional exhaled nitric oxide is produced by airway epithelial cells in response to type 2 cytokines, particularly interleukin-13 and interleukin-4, which induce inducible nitric oxide synthase. Elevated values therefore reflect active interleukin-13 and interleukin-4-driven eosinophilic airway inflammation — a hallmark of type 2 high disease. Values at or above 25 parts per billion suggest type 2 inflammation, and values above 50 parts per billion predict stronger responses to interleukin-4 and interleukin-13 pathway blockade, including dupilumab. Fractional exhaled nitric oxide is particularly useful for identifying type 2 high disease in patients whose blood eosinophil counts are only mildly elevated, guiding biologic selection toward dupilumab rather than anti-interleukin-5 agents.
Question 14
A patient with severe asthma has a serum total IgE of 280 international units per milliliter, confirmed allergic sensitization to a perennial allergen, blood eosinophils of 520 cells per microliter, and a fractional exhaled nitric oxide of 68 parts per billion. Which of the following correctly maps the biomarker profile to the most appropriate biologic target?
Correct Answer
A — The combination of confirmed allergic sensitization with eligible IgE supports omalizumab; the elevated eosinophil count supports anti-interleukin-5 agents; the elevated fractional exhaled nitric oxide and possible comorbid atopy supports dupilumab — all three biologic classes are potentially eligible based on this profile
Rationale
Biologic selection in severe asthma is guided by a biomarker-to-drug mapping framework. Elevated IgE with confirmed allergic sensitization maps to omalizumab. Blood eosinophil count at or above 300 cells per microliter maps to anti-interleukin-5 agents such as mepolizumab, reslizumab, or benralizumab. Elevated fractional exhaled nitric oxide — particularly above 50 parts per billion — and comorbid atopic disease maps to dupilumab, which targets the shared interleukin-4 and interleukin-13 pathway. When multiple biomarkers are positive, multiple biologic classes may be eligible, and clinical factors including comorbidities, cost, route of administration, and dosing schedule guide the final selection. No single biomarker takes absolute precedence across all patients.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 34-year-old woman with severe allergic asthma has a baseline serum total IgE of 310 international units per milliliter, a positive skin test to dust mites, and blood eosinophils of 280 cells per microliter. She is started on omalizumab. Her physician schedules her to remain in the clinic for 30 minutes after each of the first three injections. Which of the following best explains the mechanism and timing of the primary safety concern driving this observation requirement?
Correct Answer
B — Omalizumab carries a risk of anaphylaxis that occurs most commonly within two hours of administration, with the highest risk during the first three doses
Rationale
Anaphylaxis is the primary acute safety concern with omalizumab, occurring in approximately 0.1 to 0.2% of patients. The reaction occurs most commonly within two hours of administration, and the risk is highest during the first three doses. For this reason, omalizumab must be administered in a healthcare setting with observation for at least 30 minutes after each of the first three injections, and patients must be equipped with an epinephrine autoinjector for use outside the clinic. Delayed anaphylaxis beyond two hours has also been reported but is less common. Serum sickness is not a recognized omalizumab adverse effect pattern. Paradoxical bronchospasm from IgE receptor upregulation is not a mechanism of omalizumab toxicity.
Question 16
A 47-year-old man with severe eosinophilic asthma has blood eosinophils of 480 cells per microliter and has required two courses of oral corticosteroids in the past year despite high-dose inhaled corticosteroid plus long-acting beta-2 agonist therapy. Mepolizumab is added to his regimen. Which of the following best explains the mechanism by which mepolizumab reduces his exacerbation frequency?
Correct Answer
D — Mepolizumab binds and neutralizes interleukin-5 directly, reducing eosinophil maturation in the bone marrow, recruitment to the airway, and survival — lowering the eosinophil burden that drives exacerbations
Rationale
Interleukin-5 is the principal growth factor, maturation signal, and survival factor for eosinophils. By binding and neutralizing interleukin-5 in the circulation, mepolizumab prevents interleukin-5 from interacting with the interleukin-5 receptor on eosinophil precursors in the bone marrow and mature eosinophils in the blood and airway tissue. The result is reduced eosinophil production, impaired recruitment to the airway, and shortened eosinophil survival — producing sustained reductions in blood and tissue eosinophil counts. In patients with eosinophilic asthma, this reduction in eosinophil burden decreases the airway inflammation that triggers exacerbations. The mechanism involving antibody-dependent cellular cytotoxicity applies to benralizumab, which targets the receptor rather than the cytokine.
Question 17
A 41-year-old woman with severe asthma that remains uncontrolled on high-dose inhaled corticosteroid plus long-acting beta-2 agonist also carries diagnoses of chronic rhinosinusitis with nasal polyps and moderate atopic dermatitis. Her blood eosinophil count is 210 cells per microliter and her fractional exhaled nitric oxide is 58 parts per billion. Her physician selects dupilumab. Which of the following best explains why dupilumab is the most appropriate biologic for this patient?
Correct Answer
A — Dupilumab blocks the interleukin-4 receptor alpha subunit, simultaneously interrupting interleukin-4 and interleukin-13 signaling, and is approved for all three of her type 2 inflammatory comorbidities — asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps
Rationale
Dupilumab is the correct biologic for this patient for two converging reasons. First, mechanistically: her elevated fractional exhaled nitric oxide of 58 parts per billion reflects active interleukin-13 and interleukin-4-driven airway inflammation — the pathway dupilumab targets by blocking the shared interleukin-4 receptor alpha subunit. Unlike anti-interleukin-5 agents, dupilumab does not require a blood eosinophil count above 300 for eligibility and is effective in patients whose dominant type 2 biomarker is elevated fractional exhaled nitric oxide. Second, her comorbidity profile is a major consideration: dupilumab is approved for moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and severe asthma — all driven by the interleukin-4 and interleukin-13 pathway. A single biologic addresses all three conditions, which neither anti-interleukin-5 agents nor omalizumab can accomplish.
Question 18
A 52-year-old woman with severe eosinophilic asthma is started on benralizumab. Her physician explains that the dosing schedule differs from other biologics: she will receive subcutaneous injections every four weeks for the first three doses, then every eight weeks thereafter. Which of the following best explains the pharmacological basis for this extended maintenance interval?
Correct Answer
C — Near-complete eosinophil depletion achieved through antibody-dependent cellular cytotoxicity during the loading phase removes the cellular target, so less frequent dosing maintains the depleted state during eosinophil regeneration
Rationale
Benralizumab's dosing schedule — every four weeks for three loading doses, then every eight weeks — reflects its mechanism of near-complete eosinophil depletion through antibody-dependent cellular cytotoxicity. The three loading doses rapidly eliminate the existing eosinophil pool from blood and tissue. Once near-complete depletion is achieved, the rate of eosinophil regeneration from bone marrow precursors determines how frequently dosing must occur to prevent reaccumulation. Because benralizumab depletes eosinophils so thoroughly during the loading phase — more completely than interleukin-5 neutralization alone achieves — less frequent dosing is sufficient during maintenance to keep eosinophil counts suppressed as new cells are produced and then cleared. This is the most convenient dosing schedule among anti-interleukin-5 class agents and reflects the depth rather than the duration of the initial depletion.